[1] Miglionico M, Mangiacapra F, Nusca A, et al. Efficacy and safety of paclitaxel coated balloon for the treatment of in-stent restenosisin high-risk patients[J]. Am J Cardiol, 2015, 116(11):1690-1694. [2] Bernardo BC, Ooi JY, Lin RC, et al. miRNA therapeu-tics:a new class of drugs with potential therapeutic appli-cations in the hear[J]. Future Med Chem, 2015, 7(13):1771-1792. [3] Sluijter JP, van Mil A, van Vliet P, et al. MicroRNA-1 and-499regulate differentiation and proliferation in hu-man-derived cardiomyocyte progenitor cells[J]. Arterio-scler Thromb Vasc Biol, 2010, 30:859-868. [4] Maeng M, Baranauskas A, Christiansen EH, et al. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versussirolimus-eluting coronary stents in patients with diabetes mellitus[J]. Catheter Cardiovasc Interv, 2015, 86(7):1161-1167. [5] Jeff Bruce, Angela B, Wei Shi, et al. Identification of a microRNA signature associated with risk of distant metas-tasis in nasopharyngeal carcinoma[J]. Oncotarget, 2015, 6(6):4537-4550. [6] Gui YJ, Yang T, Liu Q, et al. Soluble epoxide hydrolase inhibitors, t-AUCB, regulated microRNA-1and its target genes in myocardial infarction mice[J]. Oncotarget, 2017, 8(55):94635-94649. [7] Wei Y, Zhu M, Corbalan-Campos J, et al. Regulation of Csflr and Bc16 in macrophages mediates the stage-specific effects of microRNA-155on atherosclerosis[J]. Arterio-scler Thromb Vasc Biol, 2015, 35(4):796-803. [8] Mehran R, Dangas G, Abizaid AS, et al. Angiographic pauem of in-stent restenosis:classification and implica-tion for long terra outcome[J]. Circulation, 1999, 100(18):1872-1878. [9] Zhu HQ, Wang F, Dong LY, et al. MicroRNA-1modu-lates oxLDL-induced hyperlipidemia by down-regulating MLCK and ERK/p38MAPK pathway[J]. Life Sci, 2014, 107(1-2):21-26. [10] Xu C, Lu Y, Pan Z, et al. The muscle-specific microR-NAs miR-1and miR-133produce opposing effects on ap-optosis by targeting HSP60, HSP70 and caspase-9in car-diomyocytes[J]. Cell Sci, 2007, 120(17):3045-3052. [11] Zhou Q, Sun Q, Zhang Y, et al. Up-regulation of miR-NA-21expression promotes migration and proliferation of sca-1+cardiac stem cells in mice[J]. Med Sci Monit, 2016, 23(22):1724-1732. [12] Jansen F, Sch fer L, Wang H, et al. Kinetics of circulat-ing microRNAs in response to cardiac stress in patients with coronary artery disease[J]. Oncotarget, 2017, 8(55):94635-94649. [13] Erkan AF, Tanindi A, Kocaman SA, et al. Epicardial adipose tissue thickness is an independent predictor of critical and complex coronary artery disease by gensini and syntax scores[J]. Tex Heart Inst J, 2016, 43(1):29-37. [14] 李雯琦, 刘书雷, 徐明彤, 等. miRNA-1与糖尿病心肌病心肌细胞肥大相关性的初步探讨[J]. 中山大学学报(医学科学版), 2013, 34(2):170-174. [15] 刘显庆, 姜德谦, 罗玉梅, 等. 葡萄糖和胰岛素对血管内皮细胞中microRNA-21的表达影响[J]. 中南大学心血管病学, 2010, 21(6):1076-1079. [16] 张成, 章少中, 张亚洲, 等. 诱导心脏肌成纤维细胞向心肌样细胞转分化的miRNA[J]. 中国组织工程研究, 2013, 1(45):7924-7931. [17] Nakatani T, Chen T, Partridge NC, et al. MMP-13is one of the critical mediators of the effect of HDAC4 dele-tion on the skeleton[J]. Bone, 2016, 90(9):142-151. [18] 剌梅, 杨登魁, 李江, 等. 血清miRNA-1、miRNA-21检测预测PCI术后患者再狭窄的临床价值[J]. 海南医学, 2015, 28(6):923-927. [19] Feng B, Cao Y, Chen S, et al. miRNA-1regulates endo-thelin-1in diabetes[J]. Life Sci, 2014, 98(1):18-23. [20] Ji R, Cheng Y, Yue J, et al. miRNA expression signa-ture and antisense mediated depletion reveal an essential role of miRNA invascular neointimal lesion formation[J]. Circ Res, 2007, 100(11):1579-1588. |